Deflux

Type: Product
Name: Deflux
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Patent Application Titled "Process for Improving Package Warpage and Connection Reliability through Use of a Backside Mold Configuration (Bsmc)"...

Patent Application Titled "Process for Improving Package Warpage and Connection Reliability through Use of a Backside Mold Configuration (Bsmc)" Published OnlineBy a News Reporter-Staff News Editor at Politics & Government Week -- According to news reporting ... [Published HispanicBusiness.com - Aug 28 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

SALIX PHARMACEUTICALS : Updates on Second Quarter Results

Salix Pharmaceuticals reported financial and operating results for the second quarter ended June 30 , and provided other business updates.In an August 7 release, the company noted that key financial highlights include:-Results for the first six months ... [Published 4 Traders - Aug 19 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 2 reports

Salix Pharmaceuticals Beats on Q2 Earnings, Cuts Guidance

The share price of Salix Pharmaceuticals, Ltd. ( SLXP - Analyst Report ) fell 3.9% after the company announced its second-quarter results on Aug 7. Although share prices have recovered slightly, the stock is still down 3.6%.Salix posted second quarter ... [Published Zacks.com - Aug 12 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Endoscopic treatment of symptomatic vesicoureteral reflux after renal transplantation - Abstract

PURPOSE: To evaluate the success of endoscopic treatment of symptomatic vesicoureteral reflux (VUR) after renal transplantation and to identify the predictive factors of success.MATERIALS AND METHODS: Between January 2000 and December 2010, 58 patients ... [Published UroToday - Aug 12 2014]

Quotes

"This has outlined, rather broadly, the features and technical advantages of the present disclosure in order that the detailed description that follows may be better understood. Additional features and advantages of the disclosure will be described below. It should be appreciated by those skilled in the art that this disclosure may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present disclosure. It should also be realized by those skilled in the art that such equivalent constructions do not depart from the teachings of the disclosure as set forth in the appended claims. The novel features, which are believed to be characteristic of the disclosure, both as to its organization and method of operation, together with further objects and advantages, will be better understood from the following description when considered in connection with the accompanying figures. It is to be expressly understood, however, that each of the figures is provided for the purpose of illustration and description only and is not intended as a definition of the limits of the present disclosure."
"Over the last few months, we achieved a number of important milestones for our business that enhance our competitive position and expand our market opportunities. Our new digestive disease specialty sales force has made significant progress in a short period of time in increasing our prescriber base, particularly with primary care physicians. Regarding our products, on July 1 we announced the statistically significant outcome of TARGET 3 evaluating the efficacy of repeat treatment with XIFAXAN 550 for Irritable Bowel Syndrome with Diarrhea (IBS-D); on July 10 the Food and Drug Administration (FDA) approved our request which was submitted under appeal that RELISTOR Subcutaneous Injection be approved to treat opioid-induced constipation in patients taking opioids for chronic, non-cancer pain on data submitted in our supplemental NDA (sNDA) and on July 16 the FDA approved RUCONEST for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). We view all of these positive events as catalysts for Salix to amplify its growth. In addition, our pending transaction with Cosmo Technologies Limited further strengthens our position as a leading gastrointestinal- focused company, adding highly complementary pipeline products to our portfolio while enhancing our profitability."

More Content

All (8) | News (6) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (2) | Press Releases (0)
sort by: Date | Relevance
Patent Application Titled "Process for Improvin... [Published HispanicBusiness.com - Aug 28 2014]
SALIX PHARMACEUTICALS : Updates on Second Quart... [Published 4 Traders - Aug 19 2014]
Salix Pharmaceuticals Beats on Q2 Earnings, Cut... [Published Zacks.com - Aug 12 2014]
Salix Pharmaceuticals Posts Second Quarter 2014... [Published PredictWallStreet - Aug 12 2014]
Endoscopic treatment of symptomatic vesicourete... [Published UroToday - Aug 12 2014]
Salix Pharmaceuticals completes $2.6bn acquisit... [Published Pharmaceutical Business Review - Jan 03 2014]
Fact Sheet for Q-Med AB [Published Able2Act - Jul 16 2008]
Fact Sheet for Q-Med [Published Able2Act - Feb 12 2008]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.